Exocrine Pancreatic Dysfunction in Chronic Pancreatitis: A Cross-Sectional Analysis of the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies Study (PROCEED)
15 affiliations
- 1Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio
- 2Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 3Department of Statistics, Rice University, Houston, Texas
- 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas
- 5Division of Pediatric Endocrinology, University of Minnesota, Minneapolis, Minnesota
- 6Department of Surgery, Baylor College of Medicine, Houston, Texas
- 7Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana
- 8Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida
- 9Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, California
- 10Division of Gastroenterology, Hepatology, and Nutrition, Los Angeles, California
- 11Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, Indiana
- 12Division of Gastroenterology, Hepatology, and Nutrition, Mayo Clinic, Rochester, Minnesota
- 13Division of Gastroenterology, Hepatology, and Nutrition, Kaiser Permanente Division of Research, Oakland, California
- 14Department of Epidemiology and Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky
- 15Division of Gastroenterology, Hepatology, and Nutrition, University of Kentucky, Lexington, Kentucky
Abstract
Background and Aims: Changes in exocrine function are believed to be common and associated with morbidities in chronic pancreatitis (CP), but there are many limitations with previous research to characterize this issue. This study aimed to determine the prevalence of and associations for exocrine pancreatic dysfunction (EPD) in a well-characterized CP study population.
Methods: We analyzed data at enrollment from participants with definite CP enrolled in Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, an ongoing multicenter study. Participants with no known EPD prior to enrollment (ie, no clinical steatorrhea or normal testing) were offered fecal elastase-1 (FE-1) testing. EPD was defined using FE-1 ≤100 mcg/g (primary) and <200 mcg/g stool (secondary) cutoffs. Multiple imputation estimated EPD prevalence in those who did not undergo FE-1 testing. Multivariable regression identified patient- and disease-related correlates of EPD.
Results: Among 681 participants, EPD point prevalence was 59.4% using <100 mcg/g and 70% using <200 mcg/g cutoff. Among 419 with assessed EPD status, EPD (<100 mcg/g) independently associated with diabetes (odds ratio [OR] 1.91 [1.10, 3.32]), alcohol etiology (OR 2.13 [1.10, 4.11]), pancreatic calcifications (OR 2.96 [1.67, 5.24]), atrophy (OR 3.23 [1.38, 7.55]), pancreatic enzyme replacement therapy (OR 4.67 [2.84, 7.65]), and Charlson Comorbidity Index ≥2 (OR 3.33 [1.08, 10.22]). EPD prevalence was higher in those with low/normal body mass index (vs overweight/obese) and among participants with diabetes across all body mass index categories. Using the secondary cutoff, the associations for EPD were generally similar, and these participants reported significantly reduced physical function and social participation.
Conclusion: EPD is common in CP and is associated with multiple clinical features and changes in pancreatic morphology. Future evaluation should further assess the impact of EPD on nutritional parameters at initial diagnosis and during the disease course, and its response to pancreatic enzyme replacement therapy.
Related
- Intrahepatic and Intrasplenic Pancreatic Pseudocysts Following Acute Pancreatitis: A Case Report
- Endoscopic management of pancreatic duct stones and stricture in chronic pancreatitis using a fully covered self-expandable metal stent.
- Spontaneous fistulization of a giant pancreatic pseudocyst into the duodenum following acute pancreatitis: a case report
- Epidemiological Profile of Emergency Hospitalizations and In-Hospital Deaths Due to Acute Pancreatitis and Other Pancreatic Diseases in Brazil, 2015-2024
- Steroid-resistant Relapse of Autoimmune Pancreatitis with Marked Main Pancreatic Duct Dilatation Mimicking Multifocal Pancreatic Cancer
BibTeX
@article{ramsey2026exocrine,
title = {{Exocrine Pancreatic Dysfunction in Chronic Pancreatitis: A Cross-Sectional Analysis of the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies Study (PROCEED)}},
author = {Mitchell L. Ramsey and Dhiraj Yadav and Peng Yang and Liang Li and Melena Bellin and William E. Fisher and Evan L. Fogel and Christopher E. Forsmark and Phil A. Hart and Walter G. Park and Stephen J. Pandol and Temel Tirkes and Mark Topazian and Stephen Van Den Eeden and Santhi Swaroop Vege and Radmila Choate and Rachel L. Hill and Darwin L. Conwell and Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)},
journal = {Gastro Hep Advances},
year = {2026},
month = sep,
doi = {10.1016/j.gastha.2026.101121},
url = {https://doi.org/10.1016/j.gastha.2026.101121},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exocrine Pancreatic Dysfunction in Chronic Pancreatitis: A Cross-Sectional Analysis of the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies Study (PROCEED)
AU - Mitchell L. Ramsey
AU - Dhiraj Yadav
AU - Peng Yang
AU - Liang Li
AU - Melena Bellin
AU - William E. Fisher
AU - Evan L. Fogel
AU - Christopher E. Forsmark
AU - Phil A. Hart
AU - Walter G. Park
AU - Stephen J. Pandol
AU - Temel Tirkes
AU - Mark Topazian
AU - Stephen Van Den Eeden
AU - Santhi Swaroop Vege
AU - Radmila Choate
AU - Rachel L. Hill
AU - Darwin L. Conwell
AU - Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
PY - 2026
DA - 2026/09/24
JO - Gastro Hep Advances
DO - 10.1016/j.gastha.2026.101121
UR - https://doi.org/10.1016/j.gastha.2026.101121
AB - Background and Aims: Changes in exocrine function are believed to be common and associated with morbidities in chronic pancreatitis (CP), but there are many limitations with previous research to characterize this issue. This study aimed to determine the prevalence of and associations for exocrine pancreatic dysfunction (EPD) in a well-characterized CP study population. Methods: We analyzed data at enrollment from participants with definite CP enrolled in Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, an ongoing multicenter study. Participants with no known EPD prior to enrollment (ie, no clinical steatorrhea or normal testing) were offered fecal elastase-1 (FE-1) testing. EPD was defined using FE-1 ≤100 mcg/g (primary) and <200 mcg/g stool (secondary) cutoffs. Multiple imputation estimated EPD prevalence in those who did not undergo FE-1 testing. Multivariable regression identified patient- and disease-related correlates of EPD. Results: Among 681 participants, EPD point prevalence was 59.4% using <100 mcg/g and 70% using <200 mcg/g cutoff. Among 419 with assessed EPD status, EPD (<100 mcg/g) independently associated with diabetes (odds ratio [OR] 1.91 [1.10, 3.32]), alcohol etiology (OR 2.13 [1.10, 4.11]), pancreatic calcifications (OR 2.96 [1.67, 5.24]), atrophy (OR 3.23 [1.38, 7.55]), pancreatic enzyme replacement therapy (OR 4.67 [2.84, 7.65]), and Charlson Comorbidity Index ≥2 (OR 3.33 [1.08, 10.22]). EPD prevalence was higher in those with low/normal body mass index (vs overweight/obese) and among participants with diabetes across all body mass index categories. Using the secondary cutoff, the associations for EPD were generally similar, and these participants reported significantly reduced physical function and social participation. Conclusion: EPD is common in CP and is associated with multiple clinical features and changes in pancreatic morphology. Future evaluation should further assess the impact of EPD on nutritional parameters at initial diagnosis and during the disease course, and its response to pancreatic enzyme replacement therapy.
SN - 2772-5723
ER -